• Invitris
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • moc.sirtivni@ofni
Invitris -

Dr. Patrick Großmann and Dr. Kilian Vogele

Invitris, managing directors

About Invitris

Invitris is transforming the way life science companies develop protein-based drugs, To accomplish this, we developed a pioneering technology platform capable of universally synthesizing novel therapeutic modalities completely in vitro. This breakthrough  enables us to highly scale both drug discovery and production. Our achievements have earned us recognition with multiple awards and international accolades.

Our marketing strategy involves collaborating with biopharmaceutical companies to bring innovative products into their drug development pipeline. Our initial focus is on antimicrobial proteins, such as bacteriophages or endolysins, to combat the biggest health-economic threat of the coming decades:  antimicrobial resistance and antibiotic resistance in particular.

Our team currently comprises six highly ambitious entrepreneurs and scientists, many of whom were trained in Munich, and we are fortunate to have the support of renowned advisors from across the world. Our shared goal is to make a lasting impact in the pharmaceutical industry and thereby contribute to a healthier, more sustainable future.

What is your motivation?

At Invitris, we are driven by a strong passion for making a lasting impact in the pharmaceutical industry. Our goal is to revolutionize the way protein-based drugs are developed and bring innovative solutions to the market. Our technology platform, which leverages cutting-edge technologies like automation and artificial intelligence, has the potential to change the game and it is already being recognized for its groundbreaking capabilities.

One of our primary focuses is addressing the growing threat of multidrug resistant infections. Our universal technology platform enables us to synthesize different protein classes in vitro, providing a highly scalable and cost-effective solution for both drug discovery and production.

I am proud to lead a team of dedicated entrepreneurs and scientists who share this vision and are driven to make a positive impact on people’s lives. Our commitment to collaboration with biopharmaceutical companies, combined with our innovative technology, will bring Invitris to the forefront of drug development and contribute to a brighter, healthier future for all.

“The IZB is a lighthouse for innovation. We’re grateful to be part of this exceptional community. The provided space is essential for successfully implementing our pioneering ideas and leaving a lasting impact. We look forward to utilizing the resources and network offered by the IZB and contributing to its thriving ecosystem.”

Dr. Patrick Großmann und Dr. Kilian Vogele
Invitris, managing directors